Company Overview of Oxford Gene Technology IP Limited
Oxford Gene Technology IP Limited provides genetics research and biomarker solutions to advance molecular medicine worldwide. Its products include CytoSure international standards for cytogenomic arrays; CytoSure ISCA UPD arrays that allow the detection of DNA copy number variation with whole chromosome uniparental disomy; CytoSure ISCA UPD arrays that combines long oligo aCGH probes for copy number variation detection; and CytoSure Syndrome Plus v2 arrays for the detection of DNA aberrations across the genome. The company's products also comprise Aneuploidy arrays for the simplified detection of chromosome imbalances; CytoSure single cell aneuploidy arrays to detect aneuploidies when workin...
Begbroke Science Park
Begbroke, OX5 1PF
Founded in 1995
Key Executives for Oxford Gene Technology IP Limited
Executive Vice President of R&D
Compensation as of Fiscal Year 2014.
Oxford Gene Technology IP Limited Key Developments
Oxford Gene Technology Receives £200,000 Phase One Development SBRI Contract to Develop Innovative NGS Analysis Software
Jul 21 14
Oxford Gene Technology has been awarded a £200,000 phase one development contract by the Small Business Research Initiative (SBRI) healthcare competition. The contract is to develop whole genome Next Generation Sequencing (NGS) analysis software to increase the accuracy, and enhance the analysis of genomic sequence data. This landmark project has the potential to accelerate the diagnosis of cancer and rare diseases, ultimately supporting patient care and research.
Oxford Gene Technology IP Limited Launches High-Resolution, High-Throughput PGS Array
Jul 8 14
Oxford Gene Technology IP Limited has announced the launch of a new high-resolution, high-throughput pre-implantation genetic screening (PGS) microarray aimed at improving embryo screening for in vitro fertilisation (IVF). The CytoSure™ Embryo Screen Array offers eight arrays of 60,000 spots for high-resolution genome-wide aneuploidy and copy number detection in pre-implantation embryos. The microarray can screen up to 14 embryos on a single slide, which is particularly useful in embryo banking — a common procedure for advanced maternal age samples — enabling the confident identification of the best embryo for implantation. The CytoSure Embryo Screen Array is sensitive enough to work with small amounts of amplified DNA from a single embryo cell. For optimal hybridisation and maximum accuracy, the probe design of the CytoSure array exactly mirrors only the amplified DNA; regions of the genome that have not been amplified are therefore not represented, minimising the possibility of misleading results. Oligonucleotide arrays, such as the CytoSure Embryo Screen Array, typically provide lower batch-to-batch variation than alternative bacterial artificial chromosome (BAC) arrays, enabling more reliable analysis. In addition, flexibility in design and content further enhances the ability of oligonucleotide arrays to meet future research requirements.
Oxford Gene Technology IP Ltd. Launches PGS Array to Improve the Chances of Successful IVF
Jun 3 13
Oxford Gene Technology IP Ltd. announced the launch of a new pre-implantation genetic screening (PGS) array aimed at improving the chances of successful in-vitro fertilisation (IVF). The array detects chromosome number abnormalities (aneuploidy) across all 24 human chromosomes using DNA amplified from a single cell from an early-stage embryo. This allows selection of an embryo with a normal chromosomal content. The number of women receiving IVF has increased steadily, however the percentage of IVF treatments resulting in viable pregnancies is still comparatively low with chromosomal aneuploidy a leading genetic cause of unsuccessful IVF. It has been reported that 75% of eggs in women over 37 and 23% of eggs in younger women are chromosomally abnormal1. OGT’s CytoSure™ Single Cell Aneuploidy array is the first commercially available oligonucleotide aCGH product designed specifically for PGS. The array is sensitive enough to work with small amounts of amplified DNA from a single cell from an early-stage embryo. Unlike technologies such as fluorescence in situ hybridisation (FISH), the array can detect aneuploidies across the whole genome. The array allows eight samples to be run simultaneously, which is more than existing bacterial artificial chromosome (BAC) aneuploidy arrays, minimising sample-to-sample variation by reducing technical noise. The array is complemented by OGT’s CytoSure Interpret Software which analyses the data generated to produce simple, easy-to-use results. The ability to clearly identify aneuploidy is vital to make a confident and informed decision as to the chromosomal content of an embryo. The array has also been research-validated to investigate aneuploidies in first polar bodies, single blastomeres and trophectoderm biopsies.
Similar Private Companies By Industry
Recent Private Companies Transactions
Most Searched Private Companies
Sponsored Financial Commentaries